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Available online 19 February 2016Background:Heart rate variability (HRV) is a validatedmethod to establish autonomic nervous system (ANS) ac-
tivity. Rheumatoid arthritis (RA) is accompanied by ANS imbalance.We hypothesized that ANS dysfunctionmay
precede the development of RA, which would suggest that it plays a role in its etiopathogenesis.
Methods: First, we assessed HRV parameters in supine (resting) and upright (active) position in healthy subjects
(HS, n= 20), individuals at risk of developing arthritis (AR subjects, n= 50) and RA patients (RA, n= 20). Next,
wemeasured resting heart rate (RHR), a parasympathetic HRV parameter, in an independent prospective cohort
of AR subjects (n = 45). We also evaluated expression levels of the parasympathetic nicotinic acetylcholine re-
ceptor type 7 (α7nAChR) on circulating monocytes.
Findings: Both AR subjects (68 beats per minute (bpm), interquartile range (IQR) 68–73) and RA patients
(68 bpm, IQR 62–76) had a signiﬁcantly higher RHR compared to HS (60 bpm, IQR 56–63). RHRwas signiﬁcantly
higher at baseline in individualswho subsequently developed arthritis. Expression levels ofα7nAChRwere lower
in AR subjects with RHR ≥70 bpm compared to those with RHR b70 bpm, consistent with reduced activity of the
parasympathetic cholinergic anti-inﬂammatory pathway.
Interpretation: These data support the notion that autonomic dysfunction precedes the development of RA.








Autonomic imbalance, deﬁned by increased heart rate (HR) and de-
creased heart rate variability (HRV), is associated with increased mor-
bidity and mortality in patients with various diseases (Inoue et al.,
2013). Autonomic imbalance has been demonstrated in autoimmune
diseases like rheumatoid arthritis (RA), systemic lupus erythematosus,
ankylosing spondylitis and inﬂammatory bowel disease (Aydemir
et al., 2010; Borman et al., 2008; Sharma et al., 2009), where it has tra-
ditionally been considered a result of chronic inﬂammation. In RA, a
prototypic immune-mediated inﬂammatory disease, several studies
demonstrated reduced activity of the parasympathetic nervous system
(PNS), whereas others found an overactive sympathetic nervous system
in RA patients (Adlan et al., 2014; Koopman et al., 2011). HRVogy and immunology Center,




e, Stevenage, United Kingdom.
. This is an open access article undermeasurements were also shown to predict response to biological treat-
ment in RA patients (Holman andNg, 2008). These observations are rel-
evant because activation of the PNS via stimulation of the vagus nerve
and the nicotinic acetylcholine receptor type 7 (α7nAChR) can reduce
inﬂammation, which has been termed as the cholinergic anti-
inﬂammatory pathway (Borovikova et al., 2000; Van Maanen et al.,
2009). In addition to measurement of HRV, assessment of sympathetic
nervous system (SNS)-related hormones, such as epinephrine and nor-
epinephrine, is informative about autonomic dysfunction (Igari et al.,
1977; Vlcek et al., 2008).
We postulated that autonomic dysfunction may precede the de-
velopment of RA, which would suggest that it plays a role in the
etiopathogenesis of this disease. Previous studies in healthy individuals
have shown that decreasedHRVparameters are associatedwith develop-
ment of disease, such as hypertension and diabetes, as an independent
risk factor (Thayer and Lane, 2007). Individuals at risk of developing auto-
antibody positive RA can be identiﬁed by detection of the autoantibodies
IgM-rheumatoid factor (IgM-RF) and anti-citrullinated protein antibodies
(ACPA); the risk of developing arthritis is further increased by smoking,
overweight and genetic factors (Klareskog et al., 2009; Gerlag et al.,
2015). Not all identiﬁed individuals will develop RA, but the presence ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
232 F.A. Koopman et al. / EBioMedicine 6 (2016) 231–237multiple serum autoantibodies increases the risk of developing RA in two
years up to ~40% (Bos et al., 2010). Identiﬁcation of additional risk factors
is necessary to provide insight into pathogenic mechanisms contributing
to the development of clinically manifest disease, and might also lead to
development of preventive strategies.
To evaluate whether autonomic dysfunctionmight contribute to the
development of RA rather than being the result of chronic inﬂammation,
wemeasured HRV aswell as plasma levels of (nor)epinephrine, and the
expression ofα7nAChR on peripheral bloodmonocytes in individuals at
risk of developing RA, healthy subjects and RA patients. In a validation
cohort, we examined the relationship between heart rate at baseline
and development of RA after follow-up.
2. Materials & Methods
2.1. Study Subjects
RApatients (n=20), healthy subjects (HS, n=20) and individuals at
risk of developing RA (AR subjects, n = 50) were included in a prospec-
tive observational study (study cohort). A sample size calculation was
performed, whereby 18 subjects in the RA and HS groups would have
80% power to detect a difference inmean high frequency (HF) of 14.6 as-
suming a standard deviation (SD) of 15 (Evrengul et al., 2004) using a
two group t-test with 0.05 two-sided signiﬁcance level. We expected a
smaller difference between HS and AR subjects, and RA and AR subjects,
and have therefore included more AR subjects. AR subjects were deﬁned
as being positive for IgM-RF, ACPA or both, having either arthralgia, or a
positive family history for RA (phase (c) + (d) or (c) + (a), but without
any evidence of arthritis upon standardized physical examination accord-
ing to European League Against Rheumatism (EULAR) recommendations
(Gerlag et al., 2012; Scott et al., 1996). RA patients were classiﬁed accord-
ing to the 2010 American College of Rheumatology and EULAR classiﬁca-
tion criteria (Aletaha et al., 2010) and had arthritis in at least one joint,
despite a stable dose of methotrexate and in some patients prednisone
(n = 4, median dose 6.25 mg per day, interquartile range (IQR) 5–
9.4 mg per day) for at least one month. HS were negative for IgM-RF
andACPA. Individualswith ahistory of cardiovascular or neurological dis-
ease, diabetes, anti-hypertensive treatment, active infection or use of an-
tibiotics in the 7 days preceding study assessments were excluded. The
study was performed according to the principles of the Declaration of
Helsinki, approved by the institutional review board of the Academic
Medical Center (AMC), the Netherlands (reference NL34802.018.10),
and all study subjects gave written informed consent.
A second, independent at risk (AR) cohort (validation cohort) was
used to validate the results. This cohort was started at the Department
of Clinical Immunology and Rheumatology AMC in 2005 and has been
described before (de Hair et al., 2013, 2014). Similar in- and exclusion
criteria were used as described above.
2.2. Study Design
In the study cohort, during one single visit demographics, anthropo-
metric data, smoking and alcohol status, medical history, RA medication
history and current medication were obtained between 8:30 and 10 am,
after patients had fasted for 8 to 10 h. Continuous heart rate (HR) and
blood pressure (BP) measurements were obtained non-invasively using
ﬁnger arterial pressure waveform recording of the left hand by Nexﬁn
(Edwards Lifesciences, BMEYE B.V. Amsterdam, the Netherlands), a vali-
dated method to assess HRV parameters (Rang et al., 2004; Prevoo
et al., 1995). The recording session contained two parts: ten-minute peri-
od in supine (resting) position, and a ten-minute period of orthostatic
stress in upright (active) position. Individualswere allowed to equilibrate
to the positional change before data were collected, followed by assess-
ment of RA disease activity (Disease Activity Score of 28 joints (DAS28)
with erythrocyte sedimentation rate (ESR) (Prevoo et al., 1995)) and a
blood draw.In the validation cohort we determined vital signs at yearly visits, in-
cluding resting heart rate (RHR) in sitting position, using an automated
monitor system. This measurement took place in non-fasting state ei-
ther in the morning or the afternoon.
2.3. Analysis of Heart Rate Variability Parameters
HRV recordings were analyzed as described before (Rang et al.,
2004) according to Task Force Guidelines (Anon., 1996). A period of
≥250 consecutive heart beats without interfering signals was selected
for both positions. HRV parameter analysis is categorized into time
and frequency domain (TD, FD) analysis. TD parameters are: HR, BP, re-
spiratory rate (RR), standard deviation of all beat-to-beat intervals
(SDNN) and root mean square of successive differences (RMSSD). RHR
and SDNN are mainly inﬂuenced by the PNS, while in upright position
the SNS becomesmore active. RMSSD reﬂects PNS activity in both posi-
tions. FD parameters of the pulse interval were determined as described
before (Zhang et al., 2013) by in-house developed digital Fourier trans-
form(DFT,Matlab, courtesyW.J. Stok,MSc). The FDparameter for PNS is
HF (0.15–0.40 Hz) and of both SNS and PNS are low frequency (LF:
0.04–0.15Hz) and LF/HF ratio. LF expressed in normalized units (nu) in-
stead of ms2 shows the inﬂuence of the SNSmore distinctly, as it is con-
trolled for total power and very low frequency (TP and VLF) (Anon.,
1996). Furthermore, gain of the baroreceptor reﬂex sensitivity (BRS)
was calculated from the transfer from systolic BP to heart period in
the LF-band, representing ability of the cardiovascular system to coun-
teract beat-to-beat changes in BP. Overall, lowered vagal efferent results
in lower HRV parameters, except for HR, RR and LF/HF ratio which
increase.
2.4. Measurement of Norepinephrine, Epinephrine and α7nAChR Expres-
sion in Peripheral Blood
Norepinephrine and epinephrine in peripheral blood could be mea-
sured in 16/20 (80%)HS, 43/50 (86%) AR subjects and 19/20 (95%) RApa-
tients from the study cohort. Fourteen AR subjects gave informed consent
for additional peripheral blood samples to measure α7nAChR expression
on monocytes. Assays are described in the Methods Appendix.
2.5. Statistics
Data are presented as median with IQR. Demographic data from in-
dividuals enrolled in the study and validation cohorts were analyzed
with non-parametric tests (Kruskal–Wallis test, Mann–Whitney U
test) if not normally distributed or by parametric tests (analysis of var-
iance (ANOVA), Student's t-test) if normally distributed. Categorical de-
mographic variables were tested using Pearson's Chi-Square test. HRV
parameters and SNS-related hormones were analyzed using multivari-
ate linear regression analysis with following confounding factors: age,
gender, bodymass index (BMI), smoking pack years and plasma triglyc-
erides. Confounders were chosen based on the literature (Valentini and
Parati, 2009) and differences between the groups in the study cohort.
The study cohort was designed to evaluate changes in AR subjects com-
pared to RA patients and HS rather than to compare RA and HS. In the
validation cohort Cox's proportional hazard regression analysiswasper-
formed to evaluate the association of RHR with arthritis development,
taking follow-up time and the following potentially confounding factors
into account: age, gender, BMI and smoking pack years. Plasma triglyc-
erides were available in a subset of individuals from the validation co-
hort and these were not included as confounder. Medication was
considered as confounding factor as well. There is no known inﬂuence
of disease-modifying antirheumatic drugs (DMARDs), or prednisone
on HRV parameters. Nonsteroidal anti-inﬂammatory drugs (NSAIDs)
are known to inﬂuence the cardiovascular system (Bhala et al., 2013;
Antman et al., 2007) and could therefore inﬂuence HRV. Adding NSAIDs
as a confounder did not alter results of the study in either cohort, and
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related hormones are not inﬂuenced by DMARD or NSAID use, but pred-
nisone use may lower (nor)epinephrine levels (Harle et al., 2006;
Golczynska et al., 1995), and prednisone was included as an additional
confounder in the analysis of these parameters. P-values b0.05 were
considered statistically signiﬁcant.
2.6. Role of the Funding Source
The study was funded by the FP7 HEALTH program under grant
agreement FP7-HEALTH-F2-2012-305549 and theDutchArthritis Foun-
dation grant 09-1-307. None of the funding sources had any role in de-
sign or conduct of the study; the collection, management, analysis, or
interpretation of the data; or the preparation, review, or approval of
the manuscript.
3. Results
3.1. Demographics Study Cohort
Demographics of the study cohort are described in Table 1. As ex-
pected, AR subjects tended to be younger than RA patients. Signiﬁcantly
more ‘ever smoker's’ and ‘smoking pack years’ were identiﬁed in ARTable 1
Demographics study cohort.
HS (n = 20) AR subjects
(n = 50)
RA (n = 20) P-valuea
Age (years) 49 (39–56) 47 (40–53) 56 (45–64) 0.078






Alcohol use: n (%) 15 (75) 27 (54) 10 (50) 0.20
Current smoker: n (%) 2 (10) 14 (28) 4 (20) 0.25
Ever smoker: n (%) 3 (15) 21 (42) 10 (52.6) 0.038
Cigarettes/day 0 (0–0) 0 (0–3) 0 (0–0) 0.29
Packyears 0.0 (0.0–0.0) 0.0 (0.0–11) 2.5 (0.0–15.0) 0.054
Cholesterol total
(mmol/L)
5.3 (4.8–6.2) 5.5 (4.7–6.3) 5.20 (4.5–5.7) 0.28
HDL (mmol/L) 1.8 (1.4–2.0) 1.6 (1.2–1.9) 1.5 (1.2–1.7) 0.31
LDL (mmol/L) 3.3 (2.6–3.8) 3.4 (2.7–4.0) 3.2 (2.7–3.7) 0.48
Triglycerides
(mmol/L)
0.7 (0.6–1.0) 0.9 (0.7–1.1) 1.1 (0.9–1.4) 0.032
Total cholesterol/HDL
ratio
3.1 (2.7–4.3) 3.5 (2.8–4.1) 3.5 (2.9–3.9) 0.71
Glucose (mmol/L) 5.0 (4.7–5.4) 5.1 (4.8–5.4) 5.1 (4.8–5.7) 0.84
RF positive: n (%) 0 (0) 31 (62) 15 (75) b0.0001
RF titer (kU/L) 3 (1–12) 92 (18–174) 217 (53–379) b0.0001
ACPA positive: n (%) 0 (0) 33 (66) 16 (80) b0.0001
ACPA titer (kAU/L) 4 (1–5) 96 (4–512) 220 (57–1187) b0.0001
Disease duration
(months)
NA NA 20 (4–91)
VAS GDA (mm) NA 26 (13–53) 44 (25–70) b0.0001
TJC28 (n) 0 (0–0) 1 (0–2) 5 (3–8) b0.0001
SJC28 (n) 0 (0–0) 0 (0–0) 2 (2–4) b0.0001
ESR (mm/h) 5 (2–11) 5 (2–10) 15 (9–27) b0.0001
CRP (mg/L) 1.8 (1.0–2.7) 1.5 (0.8–3.9) 5.6 (1.9–10.5) 0.001
DAS28 NA NA 4.32 (3.67–4.72)
NSAIDs: n (%) 0 (0) 13 (27) 10 (50) 0.001
Corticosteroids: n (%) 0 (0) 0 (0) 4 (20) b0.0001
Methotrexate: n (%) 0 (0) 0 (0) 15 (75) b0.0001
HCQ: n (%) 0 (0) 0 (0) 2 (10) 0.028
Abbreviations: AR: at risk, HS: healthy subjects; RA: rheumatoid arthritis; BMI: bodymass
index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; RF: rheumatoid fac-
tor; ACPA: anti-citrullinated protein antibodies; VAS GDA: visual analogue scale (range
0–100 mm) global disease activity; TJC28: tender joint count of 28 joints; SJC28: swollen
joint count of 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein;
DAS28: disease activity score of 28 joints; NSAIDs: non-steroidal anti-inﬂammatory
drugs; HCQ: hydroxychloroquine; NA: not applicable.
a Analysis with non-parametric tests (Kruskal–Wallis test) if not normally distributed
or parametric tests (analysis of variance (ANOVA)) if normally distributed. Categorical de-
mographic variables tested using Pearson's Chi-Square test. Data presented asmedian (in-
terquartile range) or number (percentage).subjects and RA patients compared to HS. Plasma triglyceride levels
were higher in AR subjects and RA patients than in HS, but there was
no difference in other lipid levels. RA patients had active disease, as de-
ﬁned by DAS28 above 3.2 (Prevoo et al., 1995). The mean follow-up
time of study cohort was 18.2 months (standard deviation (SD)
7.6 months) during 4/50 individuals (8%) developed arthritis.
3.2. Lower Parasympathetic Activity in AR Subjects
AR subjects (study cohort) had a signiﬁcantly higher RHR (68 beats
per minute (bpm)) compared to HS (60 bpm, p = 0.006), and similar
RHR compared to RA patients (68 bpm, p = 0.38, Fig. 1A, Table 2). HR
in upright position was also signiﬁcantly higher in AR subjects than in
HS (80 bpm versus 75 bpm, p = 0.045), and similar to RA patients
(81 bpm). Elevated RHR is mainly a consequence of lower PNS (vagus
tone) activity and elevatedHR in upright position is a result of autonom-
ic imbalancewith lower PNS and higher SNS activity. Other HRV param-
eters in AR subjects were numerically lower compared to HS, but still
higher compared to RApatients (Table 2), indicating that the autonomic
changes in the AR subjects were not as pronounced on group level com-
pared to the RA group. Thiswould be consistentwith the fact that not all
AR subjects will develop disease. Next we used a cut-off rate for RHR of
70 bpm, as previous work has shown that RHR ≥70 bpm is an undesir-
able prognostic sign for morbidity andmortality in cardiovascular stud-
ies (Inoue et al., 2013). RHRwas ≥70 bpm in 3/20 (15%) of the HS, 20/50
(40%) of AR subjects and 10/20 (50%) of RA patients.When dichotomiz-
ing AR subjects at RHR of 70, it became clear that those with a RHR
≥70 bpm displayed lower parasympathetic activity with signiﬁcantly
lower SDNN, RMSSD, LF (ms2), HF (ms2) and BRS in both positions. LF
(nu), HF (nu), MAP, RR and LF/HF ratio were not altered (Table 3).
3.3. Higher Risk of Arthritis Development With Increased Heart Rate at
Baseline
Having shown higher resting HR in AR subjects in the study cohort,
we next evaluated RHR in a similar, independent validation cohort,
and related RHR at baseline to development of arthritis. Demographics
of the validation cohort are shown in Appendix Table 1; 14/45 (31.1%)
individuals developed arthritis after follow-up (31.7 months, SD
25.0 months). RHR at baseline was signiﬁcantly higher in individuals
who developed arthritis after follow-up (n = 14, 73.8 vs 65.8 bpm,
p=0.018, Fig. 1B) compared to thosewhodid not develop arthritis dur-
ing follow-up (n= 31). In a Cox's regression analysis, taking follow-up
time and confounders in consideration, RHRwas associatedwith arthri-
tis development over time (hazard ratio 1.098: 95% CI 1.012–1.191, p=
0.025). Thus, these data are consistent with the notion that altered au-
tonomic function precedes the development of clinically manifest RA.
3.4. Lower α7nAChR Expression in AR Subjects with RHR ≥70 bpm
AR subjects with RHR ≥70 bpm (n = 6) had signiﬁcantly lower
α7nAChR expression levels on peripheral blood monocytes (p =
0.013) than AR subjectswith RHR b70 bpm (n=8), consistentwith de-
creased activity of the cholinergic anti-inﬂammatory reﬂex. Alpha-
7nAChRwas expressed on 47% (IQR 36.3–54.6) ofmonocytes in AR sub-
jects with RHR ≥70 bpm, while in AR subjects with RHR b70 bpm 69.6%
(IQR 64.9–73.5) of monocytes were positive for α7nAChR (Fig. 2).
3.5. Hormonal Changes: AR Subjects Have Increased Norepinephrine Levels
Norepinephrine levels were higher in AR subjects compared to HS
(p = 0.012), and there was a non-signiﬁcant trend towards higher
levels compared to RApatients (Table 4). Therewasnodifference in epi-
nephrine levels between the groups.
Fig. 1.Resting heart rate in healthy subjects, AR subjects andRA patients (A) and resting heart rate inAR subjects that developed arthritis after follow-up (B). Abbreviations: AR: at risk, HS:
healthy subjects; RA: rheumatoid arthritis; bpm: beats per minute, *p b 0.05, **p b 0.01.
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RA patients had signiﬁcantly higher HR in both positions (supine:
p = 0.002, upright: p = 0.010) compared to HS, indicating less PNS ac-
tivity. SDNN, RMSSD, HF and BRS were all lower in RA compared to HS
(Table 2 and Appendix Table 2) in upright position. LF (ms2) was signif-
icantly lower in RA patients compared to HS and AR subjects in upright
position, but evaluating LF (nu) did not show signiﬁcant changes.4. Discussion
Results presented here show that lower parasympathetic activity, as
revealed by lower HRV and elevated RHR in AR subjects and RA patients
compared to healthy subjects. Decreased vagus nerve tone was similar
in AR subjects and established RA patients. In a similar, independent
validation cohort RHR was signiﬁcantly higher in individuals who
subsequently developed arthritis. AR subjects with RHR ≥70 bpm dem-
onstrate lower α7nAChR levels on peripheral monocytes than AR sub-
jects with RHR b70 bpm. Furthermore, the sympathetic hormone
norepinephrine is elevated in AR subjects. Taken together, these pro-
spective observational studies indicate an altered autonomic functionTable 2
Heart rate variability parameters in supine (Sup, resting) and upright (Upr, active) position in th
paring AR subjects with HS and RA.
HS AR subjects
Sup Upr Sup Upr
Time domain
Heart Rate (bpm) 60 (56–63) 75 (67–79) 68 (61–73) 80 (74–87)
MAP (mm Hg) 85 (79–95) 95 (89–100) 88 (79–97) 96 (89–110)
RR (breaths/min) 14 (12–17) 13 (12–16) 14 (12–17) 14 (13–16)
SDNN (ms) 36 (30–46) 38 (33–42) 37 (26–52) 31 (25–41)
RMSSD (ms) 23 (20–45) 17 (13–22) 26 (18–38) 15 (12–20)
Frequency domain
LF (ms2) 355 (212–492) 385 (161–827) 267 (128–704) 246 (124–465
LF (nu) 31 (22–45) 44 (26–59) 30 (19–45) 40 (31–55)
HF (ms2) 286 (177–987) 181 (91–355) 313 (165–628) 155 (96–263)
HF (nu) 41 (25–53) 25 (16–36) 42 (32–52) 28 (22–37)
LF/HF ratio 0.7 (0.5–1.6) 1.6 (1.1–3.0) 0.8 (0.5–1.2) 1.5 (0.9–2.0)
BRS (ms/mm Hg) 8.4 (5.6–12.1) 4.5 (3.5–7.4) 6.9 (4.6–10.5) 4.2 (2.6–5.5)
Abbreviations: AR: at risk subjects, HS: healthy subjects; RA: rheumatoid arthritis; Sup: supine
terial pressure; mmHg:millimeter of mercury; RR: respiratory rate; SDNN: standard deviation
ences of successive NN intervals; LF: low frequency; nu: normalized units; HF: high frequency;
a Multivariate linear regression analysis comparingAR subjectswithHS and RApatients takin
plasma triglycerides. Data presented as median with interquartile range.preceding the development of clinically manifest disease, which could
therefore be part of the pathogenesis of RA development.
In the resting state, HR ismostly under inhibitory control by the PNS,
while in active, upright position the SNS becomes more active to the
vasculature and their balance regulates appropriate HR increase
(Valentini and Parati, 2009). Elevated RHR in AR subjects and RA pa-
tients clearly indicates lower parasympathetic activity compared to
HS. HRV parameters are dependent on HR; e.g. increased HR results in
decreased HRV parameters (Monfredi et al., 2014). Elevated RHR
(≥70 bpm) is therefore accompanied by signiﬁcantly lower HRV para-
sympathetic parameters in both positions. Increased RHR at baseline
was associated with subsequent arthritis development, as we could
show in an independent cohort of individuals at risk of RA.
Expression levels of the parasympathetic receptor α7nAChR on pe-
ripheral blood monocytes could be evaluated in a subset of AR subjects.
Expression levels were signiﬁcantly decreased in individuals with RHR
≥70 bpm compared to those with RHR b70 bpm. Alpha-7nAChR is
expressed on many different immune cells (Koopman et al., 2011); it
is currently not known how expression levels are regulated. Binding of
acetylcholine, produced by the vagus nerve (PNS) and immune cells,
to α7nAChR has an immunosuppressive effect (Koopman et al., 2014).










68 (62–76) 81 (74–92) 0.006 0.045 0.38 0.28
88 (79–95) 101 (87–105) 0.66 0.38 0.19 0.75
15 (11–17) 16 (14–18) 0.64 0.27 0.83 0.23
26 (20–39) 26 (19–32) 0.58 0.045 0.14 0.45
21 (16–35) 11 (10–15) 0.17 0.014 0.75 0.18
) 154 (113–296) 113 (71–186) 0.59 0.074 0.67 0.24
39 (27–45) 37 (27–44) 0.77 0.79 0.12 0.37
158 (124–301) 126 (60–166) 0.29 0.12 0.39 0.45
46 (31–55) 31 (21–36) 0.26 0.46 0.43 0.85
0.9 (0.4–1.5) 1.1(0.7–1.7) 0.45 0.75 0.55 0.63
5.9 (4.2–7.9) 3.1(2.5–3.7) 0.19 0.13 0.72 0.39
(resting) position: Upr: upright (active) position; bpm: beats per minute; MAP: mean ar-
of the NN intervals; ms: milliseconds; RMSSD: the square root of themean squared differ-
BRS: baroreceptor reﬂex sensitivity; ms/mm Hg: milliseconds per millimeter of mercury.
g the following confounding factors into account: age, gender, BMI, smokingpack years and
Table 3
Resting heart rate (RHR) divided in b and ≥70 beats per minute (bpm) in AR subjects (study cohort).
AR subjects RHR b 70 bpm AR subjects RHR ≥ 70 bpm P-valuea
Sup Upr Sup Upr Sup Upr
Time domain
MAP (mm Hg) 88 (78–95) 95 (88–109) 88 (83–99) 96 (90–112) 0.71 0.80
RR (breaths/min) 14.2 (12–16.8) 14.7 (12.9–17.1) 13.1 (11.7–18.2) 13.4 (12.3–16.2) 0.89 0.50
SDNN (ms) 42.1 (33.1–62.1) 34.1 (27.6–44.9) 27.2 (21.6–37.6) 26.1 (19.3–35.5) b0.0001 b0.0001
RMSSD (ms) 29.4 (20.1–53.6) 16.3 (13.5–23.4) 19.4 (13.1–31.8) 12.5 (9.7–18) b0.0001 0.002
Frequency domain
LF (ms2) 327 (197–986) 362 (174–588) 194 (64–465) 175 (86–344) 0.003 0.012
LF (nu) 25 (17–41) 44 (27–59) 35 (21–48) 38 (31–48) 0.19 0.62
HF (ms2) 491 (247–1210) 162 (111–316) 192 (98–407) 127 (67–231) b0.0001 0.022
HF (nu) 41 (29–54) 26 (22–34) 43 (33–49) 32 (24–38) 0.32 0.63
LF/HF ratio 0.71 (0.47–1.16) 1.74 (0.93–2.6) 0.87 (0.47–1.38) 1.24 (0.95–1.73) 0.12 0.68
BRS (ms/mm Hg) 9.3 (6.7–15.5) 5.1 (3.6–6.1) 4.6 (3.5–6.7) 2.7 (2.1–4.4) b0.0001 b0.0001
Abbreviations: AR: at risk, RHR: resting heart rate; bpm: Sup: supine (resting) position: Upr: upright (active) position; bpm: beats per minute; MAP: mean arterial pressure; mmHg:mil-
limeter of mercury; RR: respiratory rate; SDNN: standard deviation of the NN intervals; ms: milliseconds; RMSSD: the square root of the mean squared differences of successive NN in-
tervals; LF: low frequency; nu: normalized units; HF: high frequency; BRS: baroreceptor reﬂex sensitivity.
a Multivariate linear regression analysis with age, gender, BMI, smoking pack years and plasma triglycerides as confounders. Data presented as median with interquartile range.
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clinically manifest RA.
Levels of the sympathomimetic hormone norepinephrine were sig-
niﬁcantly increased in AR subjects compared to HS, and there was a
trend towards higher levels compared to RA patients. Norepinephrine
levels in peripheral blood depend on release, turn over and clearance,
and may with care be interpreted as an estimate of overall sympathetic
activity (Adlan et al., 2014). Norepinephrine levels in established RA
have been reported to be increased (Igari et al., 1977; Vlcek et al.,
2008) or similar compared to HS (Palm et al., 1992; Vlcek et al., 2012).
The role of increased norepinephrine levels in AR subjects is not clear.
Catecholamine depletion before onset of arthritis in animal models of
RA has an anti-inﬂammatory effect, suggesting that catecholamines
may promote the immune response before onset of disease (Koopman
et al., 2011). In our study norepinephrine levels are relatively low,
which could result in activation of the alpha adrenergic receptor types
(α-AR), mainly expressed on innate immune cells (Koopman et al.,
2011). Activation of α-AR could result in a more pro-inﬂammatory sta-
tus, but data are limited (Koopman et al., 2011). Epinephrine levels tend
to be lower (Igari et al., 1977; Vlcek et al., 2008) in RA compared to
healthy controls or show similar levels (Vlcek et al., 2012; Hirano
et al., 2001). In our study we did not ﬁnd differences in epinephrine
levels between the groups.Fig. 2. Expression levels of the parasympathetic receptor, nicotinic acetylcholine receptor
type 7 (α7nAChR) on peripheral blood CD14+monocytes AR subjects with resting heart
rate b and ≥70 bpm. Abbreviations:α7nAChR: nicotinic acetylcholine receptor type 7, AR:
at risk, RHR: resting heart rate, bpm: beats per minute, *p b 0.05.Several studies have evaluated the autonomic balance in established
RA patients and demonstrated autonomic changes using various HRV
parameters (Aydemir et al., 2010; Evrengul et al., 2004; Goldstein
et al., 2007; Lazzerini et al., 2013). Most of these studies did not adjust
for confounding factors of HRV parameters with multivariable analysis,
despite known inﬂuence of confounders, such as age and sex identiﬁed
in large cohorts (Valentini and Parati, 2009). In our study PNS activity
was attenuated in RA patients compared to HS, as HR was signiﬁcantly
higher in both positions. As a result, other HRV parameters were
lowered, but only statistically signiﬁcant in active position. LF (nu) as
a more distinct parameter of the SNS was higher in RA patients at rest,
but the difference did not reach statistical signiﬁcance. Overall, these
ﬁndings are consistent with decreased parasympathetic activity in RA
patients with little indication of an overactive sympathetic system,
which is in line with the literature (Adlan et al., 2014).
A limitation of this study is that continuous BP and HR measure-
ments were only available in the study cohort. However, automated
BP and HR measurements are also used in other studies and we were
able to show excellent correlation between continuous and automated
BP and HR measurements in the study cohort (Pearson's test r = 0.78,
p b 0.001), indicating that single BP and HRmeasurements provide reli-
able data. Finally, we did not investigate the level of physical activity or
chronic stress in the study subjects, which could have provided interest-
ing information with regard to the cause of the decreased vagus nerve
activity.
Data presented here are consistent with a pathogenic role of the au-
tonomic nervous system in the development of RA. Could these ﬁndings
help to develop preventive strategies? It is tempting to speculate that
decreasing RHR by for instance exercise or meditation (Janse van
Rensburg et al., 2012; Nesvold et al., 2012; Routledge et al., 2010)
could reduce the risk of transition of preclinical RA to clinically manifest
RA. Alternatively, a bioelectronics approach aimed at stimulation of the
vagus nerve might be explored as a preventive intervention in subjects
at high risk of developing RA (Koopman et al., 2014). Clearly, the possi-
ble value of such interventions needs to be demonstrated in future
studies.
In conclusion, we have found that autonomic imbalance precedes
the development of established RA, which could also be relevant for
other immune-mediated inﬂammatory diseases. This work supports
the rationale for future studies on measures aimed at prevention of RA
by restoring the balance in the nervous systembefore arthritis develops.
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